Ivacaftor deuterated

Drug Profile

Ivacaftor deuterated

Alternative Names: C-10355; C-10358; CTP-656; D-ivacaftor; Deuterated ivacaftor

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator Concert Pharmaceuticals
  • Class Amides; Aminophenols; Organic deuterium compounds; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 06 Mar 2017 Concert Pharmaceuticals enters into an asset purchase agreement with Vertex Pharmaceuticals to acquire all rights to Ivacaftor deuterated
  • 20 Jan 2017 Ivacaftor deuterated receives Orphan Drug status for Cystic fibrosis in USA
  • 17 Jan 2017 Concert plans a phase II trial for Cystic fibrosis in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top